In June 2021, the FDA approved the use of the GLP-1 receptor agonist semaglutide for weight loss, in a 2.4-mg/week subcutaneous dose. The drug is indicated as an adjunct to diet and exercise for adults with an initial BMI ≥ 30 kg/m2 (obesity) and for BMI ≥ 27 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (hypertension, type 2 diabetes, or dyslipidemia). The approval was based on four phase 3 clinical trials in the STEP program involving approximately 4500 patients. The STEP 1, 2, and 4 trials reported a 15%-18% weight loss over 68 weeks in individuals with overweight or obesity who received the medication.
Phentermine, another GLP-1 receptor agonist, is available for short-term (8-12 weeks) adjunctive use as part of weight reduction regimen based on exercise, behavioral modification, and caloric restriction in management of exogenous obesity for patients with initial BMI ≥ 30 kg/m² or ≥ 27 kg/m² in presence of other risk factors (eg, controlled hypertension, diabetes, and hyperlipidemia).
Learn more about medications in the treatment and management of obesity.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Michael Weber. Fast Five Quiz: Obesity-Related Hypertension - Medscape - Aug 09, 2022.